CY1118862T1 - Νεα δικυκλικη ετεροκυκλικη ενωση - Google Patents
Νεα δικυκλικη ετεροκυκλικη ενωσηInfo
- Publication number
- CY1118862T1 CY1118862T1 CY20171100330T CY171100330T CY1118862T1 CY 1118862 T1 CY1118862 T1 CY 1118862T1 CY 20171100330 T CY20171100330 T CY 20171100330T CY 171100330 T CY171100330 T CY 171100330T CY 1118862 T1 CY1118862 T1 CY 1118862T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hydrocycle
- union
- new bicycle
- present
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα εφεύρεση στοχεύει στην παροχή ενός φαρμάκου για τη θεραπευτική αγωγή ή προφύλαξη από μια παθολογία γενικά στην οποία εμπλέκεται ο SNS, ειδικότερα νόσων όπως νευροπαθητικός πόνος, αλγαισθητικός πόνος, δυσουρία, πολλαπλή σκλήρυνση και τα παρόμοια. Η παρούσα εφεύρεση παρέχει μια ένωση που παριστάνεται με τον ακόλουθο τύπο (1) ή ένα φαρμακευτικώς αποδεκτό άλας αυτής όπου το R1 είναι ένα άτομο υδρογόνου ή τα παρόμοια, το L είναι ένας απλός δεσμός, -Ο- ή τα παρόμοια. To R2 είναι μια φαινυλο ομάδα ή τα παρόμοια, το Χ είναι ένα άτομο άνθρακα ή ένα άτομο αζώτου, και τα R3, R4, R5a, R5b, R6 και R7 είναι το καθένα ανεξαρτήτως μια υποκατεστημένη ή μη υποκατεστημένη αλκυλο ομάδα ή τα παρόμοια:
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008332796 | 2008-12-26 | ||
| PCT/JP2009/071529 WO2010074193A1 (ja) | 2008-12-26 | 2009-12-25 | 新規２環性複素環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118862T1 true CY1118862T1 (el) | 2018-01-10 |
Family
ID=42287798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100330T CY1118862T1 (el) | 2008-12-26 | 2017-03-16 | Νεα δικυκλικη ετεροκυκλικη ενωση |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8471038B2 (el) |
| EP (1) | EP2380881B1 (el) |
| JP (1) | JP5143916B2 (el) |
| KR (1) | KR101663336B1 (el) |
| CN (1) | CN102264707B (el) |
| AU (1) | AU2009331179B2 (el) |
| BR (1) | BRPI0924126B1 (el) |
| CA (1) | CA2748251C (el) |
| CY (1) | CY1118862T1 (el) |
| DK (1) | DK2380881T3 (el) |
| ES (1) | ES2620446T3 (el) |
| HK (1) | HK1163676A1 (el) |
| IL (1) | IL213690A0 (el) |
| LT (1) | LT2380881T (el) |
| MX (1) | MX2011006904A (el) |
| PL (1) | PL2380881T3 (el) |
| PT (1) | PT2380881T (el) |
| RU (1) | RU2518073C2 (el) |
| SI (1) | SI2380881T1 (el) |
| TW (1) | TWI436986B (el) |
| WO (1) | WO2010074193A1 (el) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2518073C2 (ru) * | 2008-12-26 | 2014-06-10 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Новое бициклическое гетероциклическое соединение |
| JP5667934B2 (ja) * | 2010-06-28 | 2015-02-12 | 大日本住友製薬株式会社 | 新規２環性複素環化合物からなる医薬 |
| CN101985453B (zh) * | 2010-10-18 | 2012-10-31 | 国家海洋局第三海洋研究所 | 一种4-氨基吡啶衍生物及其制备方法与应用 |
| EP3009427B1 (en) | 2011-03-03 | 2019-12-18 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| CN103796986B (zh) * | 2011-07-07 | 2015-08-19 | 庵原化学工业株式会社 | 硝基苯化合物的制备方法 |
| US20130172342A1 (en) * | 2011-12-28 | 2013-07-04 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
| US9944634B2 (en) * | 2012-10-31 | 2018-04-17 | Raqualia Pharma Inc. | Pyrazolopyridine derivatives as TTX-S blockers |
| JP2016169161A (ja) * | 2013-07-19 | 2016-09-23 | 大日本住友製薬株式会社 | 新規イミダゾピリジン化合物 |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| JP6463580B2 (ja) | 2013-12-13 | 2019-02-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ |
| JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| US20210393604A1 (en) * | 2017-03-15 | 2021-12-23 | Sumitomo Dainippon Pharma Co., Ltd. | Novel benzimidazolone compound and pharmaceutical use thereof |
| WO2018168899A1 (ja) | 2017-03-15 | 2018-09-20 | 大日本住友製薬株式会社 | ベンズイミダゾール誘導体の製造方法 |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| BR112021000183A8 (pt) * | 2018-07-19 | 2022-12-06 | Sumitomo Dainippon Pharma Co Ltd | Preparação medicinal para uso externo |
| US20230062053A1 (en) | 2019-01-10 | 2023-03-02 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| US20240100022A1 (en) | 2020-12-23 | 2024-03-28 | Sumitomo Pharma Co., Ltd. | Oral solid preparation |
| US20240285596A1 (en) | 2021-06-04 | 2024-08-29 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| EP4347032A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| CR20230586A (es) | 2021-06-04 | 2024-05-07 | Vertex Pharma | N-(hydroxyalquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio |
| JP2024520646A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体 |
| AU2022286511A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023256603A1 (en) | 2022-04-22 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023255771A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19705450A1 (de) * | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
| CA2425185A1 (en) | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Benzimidazole and indole derivatives as crf receptor modulators |
| CA2429630A1 (en) * | 2000-11-21 | 2002-05-30 | Vertex Pharmaceuticals Incorporated | Imidazole and benzimidazole caspase inhibitors and uses thereof |
| EP1678145A2 (en) * | 2003-10-28 | 2006-07-12 | Vertex Pharmaceuticals Incorporated | Benzimidazoles useful as modulators of ion channels |
| WO2008033739A2 (en) * | 2006-09-12 | 2008-03-20 | Neurogen Corporation | Benzimidazole carboxamide derivatives |
| WO2009079011A1 (en) | 2007-12-19 | 2009-06-25 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| RU2518073C2 (ru) * | 2008-12-26 | 2014-06-10 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Новое бициклическое гетероциклическое соединение |
| BR112021000183A8 (pt) * | 2018-07-19 | 2022-12-06 | Sumitomo Dainippon Pharma Co Ltd | Preparação medicinal para uso externo |
-
2009
- 2009-12-25 RU RU2011131048/04A patent/RU2518073C2/ru active
- 2009-12-25 SI SI200931642A patent/SI2380881T1/sl unknown
- 2009-12-25 WO PCT/JP2009/071529 patent/WO2010074193A1/ja active Application Filing
- 2009-12-25 BR BRPI0924126-4A patent/BRPI0924126B1/pt active IP Right Grant
- 2009-12-25 PT PT98349897T patent/PT2380881T/pt unknown
- 2009-12-25 MX MX2011006904A patent/MX2011006904A/es active IP Right Grant
- 2009-12-25 CN CN200980152533.9A patent/CN102264707B/zh active Active
- 2009-12-25 AU AU2009331179A patent/AU2009331179B2/en active Active
- 2009-12-25 JP JP2010544140A patent/JP5143916B2/ja active Active
- 2009-12-25 DK DK09834989.7T patent/DK2380881T3/en active
- 2009-12-25 TW TW098144921A patent/TWI436986B/zh active
- 2009-12-25 CA CA2748251A patent/CA2748251C/en active Active
- 2009-12-25 US US13/141,301 patent/US8471038B2/en active Active
- 2009-12-25 ES ES09834989.7T patent/ES2620446T3/es active Active
- 2009-12-25 KR KR1020117017450A patent/KR101663336B1/ko active IP Right Grant
- 2009-12-25 PL PL09834989T patent/PL2380881T3/pl unknown
- 2009-12-25 LT LTEP09834989.7T patent/LT2380881T/lt unknown
- 2009-12-25 EP EP09834989.7A patent/EP2380881B1/en active Active
-
2011
- 2011-06-21 IL IL213690A patent/IL213690A0/en active IP Right Grant
-
2012
- 2012-05-02 HK HK12104295.0A patent/HK1163676A1/xx not_active IP Right Cessation
-
2013
- 2013-05-15 US US13/895,089 patent/US20130303535A1/en active Pending
-
2017
- 2017-03-16 CY CY20171100330T patent/CY1118862T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2380881A4 (en) | 2013-01-09 |
| SI2380881T1 (sl) | 2017-05-31 |
| ES2620446T3 (es) | 2017-06-28 |
| AU2009331179A1 (en) | 2011-08-11 |
| DK2380881T3 (en) | 2017-05-08 |
| IL213690A0 (en) | 2011-07-31 |
| US20130303535A1 (en) | 2013-11-14 |
| BRPI0924126A2 (pt) | 2020-08-11 |
| RU2518073C2 (ru) | 2014-06-10 |
| AU2009331179B2 (en) | 2014-09-18 |
| PT2380881T (pt) | 2017-04-18 |
| US20110294804A1 (en) | 2011-12-01 |
| KR20110098971A (ko) | 2011-09-02 |
| TW201028386A (en) | 2010-08-01 |
| PL2380881T3 (pl) | 2017-07-31 |
| BRPI0924126B1 (pt) | 2021-07-27 |
| CA2748251C (en) | 2016-08-02 |
| KR101663336B1 (ko) | 2016-10-06 |
| AU2009331179A2 (en) | 2011-08-11 |
| CA2748251A1 (en) | 2010-07-01 |
| RU2011131048A (ru) | 2013-02-10 |
| JP5143916B2 (ja) | 2013-02-13 |
| CN102264707B (zh) | 2014-09-03 |
| LT2380881T (lt) | 2017-04-10 |
| US8471038B2 (en) | 2013-06-25 |
| TWI436986B (zh) | 2014-05-11 |
| JPWO2010074193A1 (ja) | 2012-06-21 |
| HK1163676A1 (en) | 2012-09-14 |
| MX2011006904A (es) | 2011-07-20 |
| CN102264707A (zh) | 2011-11-30 |
| WO2010074193A1 (ja) | 2010-07-01 |
| EP2380881B1 (en) | 2017-01-25 |
| EP2380881A1 (en) | 2011-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118862T1 (el) | Νεα δικυκλικη ετεροκυκλικη ενωση | |
| CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
| CY1123308T1 (el) | Αναστολεας ινωσης | |
| MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
| TW200745034A (en) | New compounds | |
| PH12016501822A1 (en) | Cyclopropaneamine compound | |
| CY1116119T1 (el) | Παραγωγα ισοξαζολο-πυριδινης | |
| CY1107008T1 (el) | Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii | |
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| CY1114452T1 (el) | Ενωσεις πυρρολιου | |
| TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| HK1165954A1 (en) | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| RS53617B1 (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
| CY1119296T1 (el) | Ενωση δικαρβοξυλικου οξεος | |
| PH12018502012A1 (en) | Griseofulvin compound | |
| AR081893A1 (es) | Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina | |
| DE602007011434D1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| DE602006014022D1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| MX2009013775A (es) | Sustituto novedoso de piperidones sustituidas como inductor de hsp. | |
| IN2013MN00506A (el) | ||
| EA201270787A1 (ru) | 8-гидроксихинолиновые производные | |
| MX2011011716A (es) | Derivados de isoquinolina novedosos. | |
| MX2014002744A (es) | Composiciones para el cuidado oral y de la piel con base en un 3,3´-dialquil-1,1´-bifenil-2,2´-diol o un 3,3´-dialquenil-1,1´-bif enil-2,2´-diol. |